Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Market Nanosphere Products in Certain European Countries

NEW YORK (GenomeWeb News) – Nanosphere today said that Thermo Fisher Scientific will market and distribute its Verigene products in Germany, Austria, and France.

Nanosphere recently received the CE Mark for its Verigene molecular diagnostics system and certain assays targeted at the microbiology market. Financial and other terms of the agreement were not disclosed.

"The agreement will focus on Verigene products that provide rapid identification of infectious diseases and associated drug resistance, arming physicians and hospitals with clinically actionable results that improve patient care and reduce the cost of treating critical illnesses," Paul James, Thermo Fisher's European vice president and general manager for microbiology, said in a statement.

Nanosphere said that it now has distribution agreements in place for all of the major markets in Europe.

The Verigene system was initially cleared for marketing in the US in 2007, and Nanosphere has US Food and Drug Administration clearance for several assays that run on the system. Most recently, it obtained 510(k) clearance for its Verigene Staphylococcus Blood Culture Nucleic Acid Test, or BC-S.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.